936902-07-7

Usage

Uses

Used in Pharmaceutical Industry:
1H-Indole, 7-(methylthio)is used as a pharmaceutical agent for its potential antimicrobial and antiparasitic activities. Its unique properties make it a subject of interest in the development of new pharmaceuticals to combat various infections and parasitic diseases.
Used in Chemical Industry:
1H-Indole, 7-(methylthio)is used as a valuable building block in the synthesis of various complex organic molecules. Its presence in the indole class of organic compounds and the unique properties conferred by the methylthio group make it a versatile compound for use in the chemical industry.

Upstream product

• 51417-51-7 7-bromo-1H-indole 
• 2432-51-1 ethylthioacetic acid methyl ester 
• 624-92-0 Dimethyldisulphide 

Relevant academic research and scientific papers

Palladium-catalyzed intermolecular transthioetherification of aryl halides with thioethers and thioesters

Functional group transfer reactions are an important synthetic tool in modern organic synthesis. Herein, we developed a new palladium-catalyzed intermolecular transthioetherification reaction of aryl halides with thioethers and thioesters. The synthetic utility and practicality of this catalytic protocol are demonstrated in a wide range of successful transformations (>70 examples). This catalytic protocol is applicable in carbonylative coupling processes as well, and the first example of carbonylative methylthioesterification of aryl halides has been achieved. Notably, this work also provides an approach to using natural products, such as methionine and selenomethionine, as the functional group sources.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.